What is the clinical evidence from this study?

Study design: Review. Population: Marathon-associated sudden cardiac death.

What does this research mean for the field?

Although rare, marathon-associated sudden cardiac death is primarily driven by coronary artery disease in older runners and inherited conditions in younger athletes, with risk peaking late in the race and requiring targeted screening and rapid on-site resuscitation. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

May 28, 2026Open Access

Marathon-associated sudden cardiac death: a mini review of risk perception, pathophysiological mechanisms, and prevention strategies

Key Result

Marathon-associated sudden cardiac death has a low absolute incidence of approximately 0.4 to 1.7 per 100,000 finishers, with higher risk observed in men, older runners, and full-marathon participants.

Structured PICO

Population

Marathon runners

Intervention

Marathon running and preventive strategies (pre-participation screening, ECG, imaging, genetic evaluation, on-site resuscitation)

Outcome

Sudden cardiac death (SCD) and cardiac arresthard clinical

This review highlights the epidemiological patterns and etiologies of marathon-associated sudden cardiac death, emphasizing the need for precision risk stratification and standardized race-day emergency preparedness.

Limitations

Narrative mini review without formal risk-of-bias instrument or pooled estimates
Selective citation bias cannot be excluded
Inclusion restricted to English-language publications
Marathon-specific evidence remains scarce in young runners and in the long-term prognosis of CMR/CAC findings
Heterogeneity in event definitions and ascertainment methods across cited studies limits strict quantitative comparison
Non-cardiovascular exercise-related risks were not addressed

Abstract

Marathon running is widely promoted for its cardiovascular and overall health benefits, yet rare cases of sudden cardiac death (SCD) during long-distance races continue to raise substantial clinical and public health concerns. Although the absolute incidence of marathon-associated SCD is low, its catastrophic nature necessitates a clearer understanding of risk perception, epidemiological patterns, pathophysiological mechanisms, and preventive strategies. This mini review synthesizes current evidence on the incidence, demographic characteristics, etiological spectrum, and temporal features of cardiac arrest and SCD during marathon running. Available data indicate that risk is higher in men, older runners, and full-marathon participants, with most events occurring in the final phase of the race or shortly after finishing. Coronary artery disease remains the predominant cause in middle-aged and older runners, whereas inherited cardiomyopathies, congenital coronary anomalies, and myocarditis are more relevant in younger athletes. We further discuss the mechanistic basis of exercise-triggered fatal events, including acute ischemia, malignant ventricular arrhythmias, myocardial fibrosis, and inflammatory myocardial injury. Current preventive approaches, including pre-participation cardiovascular screening, electrocardiography, advanced imaging, genetic evaluation in selected individuals, and rapid on-site resuscitation systems, have improved event recognition and survival outcomes, but important controversies persist regarding optimal screening intensity, interpretation of subclinical findings, and the dose-response relationship between extreme endurance exercise and cardiovascular risk. Future efforts should prioritize precision risk stratification, longitudinal evaluation of subclinical cardiovascular abnormalities, integration of wearable monitoring technologies, and standardized race-day emergency preparedness to improve the safety of long-distance running.

Mark Helpful

Bookmark

Relay

View Full Paper